StockData

Lexicon Pharmaceuticals vs vTv Therapeutics

LXRX and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LXRX and VTVT compare

Lexicon Pharmaceuticals is the larger company, worth 12 times as much as vTv Therapeutics ($792M against $68.4M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus −29.0% for Lexicon Pharmaceuticals).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −147% at Lexicon Pharmaceuticals.

vTv Therapeutics scores higher on the StockData Score (11 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLXRXVTVT
Size and price
Market cap$792M$68.4M
Share price$1.78$17.29
Change, 1 year19.5%−43.9%
Change, 5 years−62.4%−67.7%
Beta (5Y)0.010.08
Employees8126
StockData Score
Total score511 (better)
Valuation score03 (better)
Growth score11
Performance score22
Health score25 (better)
Dividend score00
Valuation
P/S19.1×1.9× (better)
P/B4.5×0.9× (better)
Fair value$0.950$44.97
Margin of safety−87.4%61.6% (better)
Growth
Revenue growth (TTM)−29.0%216600% (better)
Revenue growth, 5Y average15.7%–
Profitability
Gross margin99.1%–
Operating margin−131%−25.1% (better)
Net margin−147%−12.9% (better)
Return on equity−40.2%−11.7% (better)
Return on invested capital−163%–
Financial health
Debt / equity0.29 (better)0.00
Current ratio13.37 (better)12.48
Altman Z-score−4.870.71 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.9%40.6%
Held by insiders–26.3%
Insider net buying, 12 months$2.8M–
Short interest, % of float–5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.